Business Context and Reporting Period
This Form 8-K, dated January 19, 2021, reports a material definitive agreement entered into by Obalon Therapeutics, Inc. (Obalon) and ReShape Lifesciences, Inc. (ReShape). The filing details a merger agreement where Obalon will acquire ReShape via a stock-for-stock transaction. The combined entity will be renamed ReShape Lifesciences, Inc.
Key Financial Metrics and Transaction Terms
This filing is a current report regarding a corporate transaction and does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels for the reporting period.
- Merger Consideration: ReShape shareholders will receive Obalon common stock based on an exchange ratio determined to result in ReShape shareholders owning 51% of the combined company immediately post-merger.
- Equity Treatment: ReShape warrants will convert to Obalon warrants. ReShape stock options will be cancelled without payment. Obalon will assume ReShape Series C Preferred Stock obligations.
- Obalon Equity: All outstanding Obalon options and restricted stock units will become fully vested at the effective time of the merger.
- Termination Fee: ReShape has deposited $1.0 million in escrow. If the merger is terminated due to ReShape's failure to obtain Nasdaq approvals or if approvals are not obtained within 30 days of shareholder meetings, ReShape must pay Obalon the $1.0 million fee.
Material Changes and Governance
The primary material change is the proposed consolidation of two medical device companies. Upon consummation:
- Corporate Name: Obalon will be renamed ReShape Lifesciences, Inc.
- Board Composition: The board will consist of the five current ReShape directors: Dan W. Gladney (Chair), Barton P. Bandy, Arda M. Minocherhomjee, Lori C. McDougal, and Gary D. Blackford (Lead Director).
- Executive Leadership: Barton P. Bandy will serve as CEO, and Tom Stankovich will serve as CFO of the combined company.
- Shareholder Support: Voting agreements have been secured with major shareholders representing approximately 86.4% of ReShape stock and 24.3% of Obalon stock to support the merger.
Guidance, Risks, and Conditions
The filing outlines several conditions precedent to the merger's consummation, including shareholder approval from both companies, Nasdaq listing approvals, and the absence of a material adverse effect. No specific financial guidance or outlook is provided in this document.
Key Risks and Contingencies:
- Failure to obtain required stockholder approvals.
- Inability to satisfy Nasdaq listing requirements for the additional shares or the combined company.
- Unexpected costs, liabilities, or delays associated with the merger.
- Operational disruption or loss of key personnel due to merger uncertainty.
- Legal proceedings or regulatory actions that could enjoin the transaction.
Investor Verification Checklist
- Verify the final Exchange Ratio once determined (must result in 51% ownership for ReShape shareholders).
- Confirm the outcome of the upcoming shareholder votes for both Obalon and ReShape.
- Monitor the status of Nasdaq listing approvals for the new shares and the combined entity.
- Review the upcoming joint proxy statement/prospectus for detailed financial data and risk factors.
- Assess the impact of the cancellation of ReShape stock options on employee retention.